Belzutifan(Welireg) is a novel therapeutic drug specifically targeting tumors associated with von Hippel-Lindau (VHL) syndrome. It inhibits tumor growth by targeting HIF-2α and is indicated for specific types of renal cell carcinoma, central nervous system hemangioblastoma, and pancreatic neuroendocrine tumors.

Indications for Belzutifan

Belzutifan offers new treatment options for several tumors associated with VHL syndrome.

Renal cell carcinoma (RCC)

Belzutifan is indicated for adult patients with VHL syndrome who require treatment for RCC. Studies have shown that the drug is effective in slowing the growth rate of tumors, providing a non-invasive treatment for patients who are not candidates for immediate surgery. For RCC patients who are unable or unwilling to undergo surgery, Belzutifan opens up a new path of hope.

Central nervous system (CNS) hemangioblastoma

In addition to RCC, Belzutifan is also approved for the treatment of CNS hemangioblastoma associated with VHL syndrome. These tumors often pose a serious health threat to patients, and the emergence of Belzutifan has opened up more treatment options for them.

By targeting HIF-2α, Belzutifan can help stabilize the disease, reduce tumor volume, and improve patients' quality of life.

Belzutifan is suitable for people

Understanding the appropriate population for Belzutifan can help better guide clinical use and determine that the most appropriate treatment is available for each patient.

Patients with VHL syndrome

Belzutifan is primarily targeted at the patient population with VHL syndrome, particularly those with renal cell carcinoma, CNS hemangioblastoma, or pancreatic neuroendocrine tumors. These patients are often at high risk of tumor recurrence and therefore require continued effective treatment.

Precautions for medication in special populations

Pregnant and lactating women, as well as men and women of childbearing potential, should take special care when using Belzutifan. In addition, for special populations such as older patients and people with renal or hepatic insufficiency, the dose should be adjusted or additional precautions should be taken on a case-by-case basis.

Clarifying the medication guidelines for special populations can maximize the safety and efficacy of medication for patients.

Dietary structure of patients with Belzutifan

A reasonable diet is important for patients during Belzutifan treatment to improve the effectiveness of treatment and reduce side effects.

The importance of a balanced diet

Maintaining a balanced diet can help maintain good health, enhance immune system function, and combat possible adverse effects such as anemia and fatigue. With adequate intake of protein, vitamins and minerals, patients are better able to cope with the challenges posed by the disease.

Avoid irritating foods

Patients are advised to avoid spicy, greasy and other irritating foods as much as possible to avoid aggravating the burden on the gastrointestinal tract or causing discomfort. It is also necessary to limit excessive sugar and salt intake.

A healthy diet not only complements the best results of medications, but also promotes an overall recovery process.